Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Plan to resubmit early Q1 to FDA

<< Previous

Bullboard Posts

Next >>

Comment by judgesmailson Mar 27, 2024 10:56pm

213 Views

Post# 35957135

RE:Plan to resubmit early Q1 to FDA

Agreed. Plan from before Christmas was pre BDT submission in early Q1 and actual BTD later in Q1.

Then January update said pre BTD in Q1 sometime and BTD in Q2.

Now it is pre BTD in Q2 and BTD submission later. Hopefully later in Q2...but not necessarily.

"The Company plans to resubmit the pre-BTD submission to the FDA in 2Q2024 for FDA review of these clarifications. Once the pre-BTD submission has been accepted by the FDA, the Company will compile a BTD submission for review by the FDA in support of the grant of a BTD approval."
.
It would be nice to understand something about the delays

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks